Palmitoylethanolamide and Luteolin: study protocols
8 study groups took Palmitoylethanolamide together with Luteolin. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Palmitoylethanolamide
8 study groups in 4 studies say how much Palmitoylethanolamide participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 500 mg to 1 g, 75% of 8 study groups.
| Daily dose | Study groups |
|---|---|
| 500 mg to 1 g | 6 |
| 1 g to 2.5 g | 2 |
Dose per serving from research: Luteolin
8 study groups in 4 studies say how much Luteolin participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 50 mg to 100 mg, 75% of 8 study groups.
| Daily dose | Study groups |
|---|---|
| 50 mg to 100 mg | 6 |
| 100 mg to 250 mg | 2 |
Commonly used together
None of these 8 study groups took Palmitoylethanolamide and Luteolin with anything else.
8 study groups
| Study | ||||
|---|---|---|---|---|
| Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo- Controlled Clinical Trial 2022 · Intervention group · Adults aged 18–80 with post-COVID-19 anosmia or hyposmia persisting at least 180 days | 700 mg | 70 mg | 90 days | 130 |
| Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial 2023 · Combined therapy (um-PEA–LUT: once daily + olfactory training) · Adults aged 18–60 with persistent anosmia or hyposmia after COVID-19 | 700 mg | 70 mg | 90 days | 76 |
| Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial 2023 · um-PEA–LUT alone (once daily) · Adults aged 18–60 with persistent anosmia or hyposmia after COVID-19 | 700 mg | 70 mg | 90 days | 48 |
| Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study 2022 · Training-Naïve 1 (PEA-LUT plus olfactory training) · Adults aged 18–80 with long COVID and persistent anosmia or hyposmia after SARS-CoV-2 infection, without prior olfactory training | 700 mg | 70 mg | 90 days | 43 |
| Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial 2023 · um-PEA–LUT alone (twice daily) · Adults aged 18–60 with persistent anosmia or hyposmia after COVID-19 | 1.4 g | 140 mg | 90 days | 40 |
| Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study 2022 · Training-Naïve 2 (PEA-LUT alone) · Adults aged 18–80 with long COVID and persistent anosmia or hyposmia after SARS-CoV-2 infection, without prior olfactory training | 700 mg | 70 mg | 90 days | 16 |
| Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study 2022 · Previously trained group (PEA-LUT plus olfactory training) · Adults aged 18–80 with long COVID and persistent anosmia or hyposmia after SARS-CoV-2 infection who had previously undergone olfactory training | 700 mg | 70 mg | 90 days | 10 |
| Co-ultramicronized palmitoylethanolamide/luteolin normalizes GABA(B)-ergic activity and cortical plasticity in long COVID-19 syndrome 2023 · PEA-LUT · Adults with fatigue and/or cognitive difficulties after mild COVID-19; age range not reported | 1.4 g | 140 mg | 8 weeks | 17 |